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AbstrAct
Objectives to demonstrate the equivalent efficacy and 
compare the safety and immunogenicity of an etanercept 
biosimilar, gP2015, with reference etanercept (etn) in 
patients with moderate-to-severe, active rheumatoid 
arthritis (ra), characterised by an inadequate response 
to synthetic or biologic disease-modifying antirheumatic 
drugs (DMarDs).
Methods in the eQUira study, eligible patients (n=376) 
were randomised 1: 1 to 50  mg gP2015 or etn 
subcutaneously, once weekly, for 24 weeks (treatment 
period 1). Patients from both groups, with at least 
moderate european league against rheumatism response 
at week 24, received gP2015 up to week 48 (treatment 
period 2). all patients continued to receive concomitant 
methotrexate at a stable dose (10–25  mg/week) until end 
of the study. the 24-week results are presented here.
Results equivalent efficacy between gP2015 and etn 
was demonstrated if the 95% ci for the difference in 
disease activity score 28-joint count c reactive protein 
(DaS28-crP) change from baseline to week 24 between 
treatment arms was contained within the prespecified 
equivalence margin range of −0.6 to 0.6. the least 
squares mean difference (gP2015–etn) in change from 
baseline in DaS28-crP up to week 24 was −0.07 (95% 
ci −0.26 to 0.12 [primary endpoint)]. the incidence of 
treatment-emergent adverse events was comparable 
between gP2015 (43.5%) and etn (49.5%). none of the 
gP2015-treated patients developed neutralising anti-drug 
antibodies (nabs) whereas 1.6% and 0.6% of patients 
in etn group were nab positive at weeks 4 and 12, 
respectively.
Conclusion in patients with ra who had an inadequate 
response to DMarDs, gP2015 demonstrated a similar 
efficacy and a comparable safety and immunogenicity 
profile with etn.
Trial registration nct02638259.
InTROduCTIOn
Etanercept is a recombinant dimeric fusion 
protein that binds to and neutralises the 
biological activity of tumour necrosis factor 
(TNF), a naturally occurring cytokine. TNF 
plays a key role in the pathogenesis of a 
Key messages
What is already known about this subject?
 ► gP2015 is an etanercept biosimilar.
 ► analytical similarity and bioequivalence between 
gP2015 and reference etanercept (etn) has been 
demonstrated.
What does this study add?
 ► gP2015 demonstrated an equivalent efficacy to etn 
in patients with rheumatoid arthritis with moderate 
to severe disease with inadequate responses to 
DMarDs, including methotrexate and biologics. no 
new safety findings were reported.
How might this impact on clinical practice?
 ► the results from this study providing evidence of 
biosimilarity between gP2015 and etn may aid clin-
ical decision-making around the use of biologics/
biosimilars in the treatment of rheumatoid arthritis.
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range of immune-mediated inflammatory diseases.1 
Etanercept is approved for the treatment of multiple 
immune-mediated inflammatory diseases including 
moderate-to-severe rheumatoid arthritis (RA)2 3 and has 
been used successfully in clinical practice over many 
years.
A biosimilar is a biologic agent that contains a similar 
version of the active substance of an already authorised 
reference biologic.4 Regulatory decisions for approval 
of biosimilars require confirmation and evaluation of 
biosimilarity between a proposed biosimilar and the 
approved reference biologic in terms of physicochemical 
characteristics, biological activity, efficacy and safety.5 6
GP2015 (Erelzi®; Sandoz Inc., Princeton, New Jersey, 
USA) is an etanercept biosimilar. Analytical similarity and 
bioequivalence between GP2015 and reference etaner-
cept (ETN; Enbrel® (European Union authorised)) has 
been demonstrated previously.7 The phase III EGALITY 
study demonstrated equivalent clinical efficacy of GP2015 
and ETN in plaque-type psoriasis.8 GP2015 is currently 
approved in the EU9 and the USA.10
The objective of the present comparative, phase III, 
EQUIRA study was to demonstrate equivalent efficacy and 
to compare the safety and immunogenicity of GP2015 
with ETN in patients with moderate-to-severe, active RA, 
who had an inadequate response to either conventional 
synthetic and/or biologic disease modifying antirheu-
matic drugs (DMARDs). Here, the results from the first 
24-week treatment period of the study are reported.
MeTHOds
study endpoints
The primary endpoint was the change from baseline in 
disease activity score 28-joint count C reactive protein 
(DAS28-CRP) up to week 24. Secondary endpoints 
were other efficacy endpoints assessed up to week 24 
including (1) change from baseline in DAS28-CRP 
scores,11 (2) proportion of patients achieving good 
and moderate European League Against Rheuma-
tism (EULAR) response12 based on DAS28-erythrocyte 
sedimentation rate (ESR), (3) proportion of patients 
achieving a 20/50/70% improvement in the American 
College of Rheumatology (ACR) core set of measure-
ments (ACR20/50/70), (4) physical function assessed 
by the Health Assessment Questionnaire Disability Index 
(HAQ-DI) score13 14 and (5) impact of fatigue on patients 
assessed by the Functional Assessment of Chronic Illness 
Therapy (FACIT) fatigue scale.15 16
Safety endpoints included adverse event monitoring 
and evaluation of local tolerability at the injection sites of 
both medications as assessed by the investigator during 
the study. The proportion of patients with anti-drug anti-
bodies (ADAs) was assessed at baseline and at weeks 2, 
4, 12 and 24 by a three-step procedure comprising a vali-
dated screening, confirmatory and titre determination 
electrochemiluminescence bridging assay.
Immunogenicity assessment
The applied method for the detection of ADAs is based 
on a bridging electrochemiluminescence assay format17 
including acid dissociation steps. Study samples were first 
analysed in a screening assay based on a 5% false-posi-
tive rate. Assay sensitivity (<100 ng/mL using a polyclonal 
ADA-positive control) and drug tolerance (50 µg/mL for 
GP2015 and ETN) was determined during method vali-
dation. Samples that were positive in the screening assay 
were subsequently analysed in a confirmatory assay based 
on a 1% false-positive rate. The titre of confirmed posi-
tive ADA samples was determined and the neutralising 
capacity of ADAs was assessed in a competitive ligand 
binding assay.
study design
EQUIRA was a 48-week, phase III, parallel-group, 
randomised, double-blind study conducted at 113 sites 
across 16 countries from November 2015 to June 2017. 
Eligible patients were randomised 1:1 to self-administer 
50 mg GP2015 or ETN subcutaneously, once weekly, for 
24 weeks (treatment period 1 [TP1]; see online supple-
mentary appendix 1 for details on the randomisation 
schedule). At week 24, patients from both treatment 
groups achieving at least a moderate treatment response 
according to EULAR response criteria (responders) 
received GP2015 up to week 48 (TP2; online supplemen-
tary figure S1).
This study was conducted in accordance with the ethical 
principles derived from the Declaration of Helsinki and 
International Conference on Harmonisation Good Clin-
ical Practices and in compliance with local regulatory 
requirements.
study population
Patients of either sex, aged ≥18 years, were included 
if they met the following criteria: (1) had RA classi-
fied according to the ACR 1987 or ACR/EULAR 2010 
criteria18 for ≥6 months before baseline; (2) had active 
disease defined as DAS28-CRP ≥3.2; (3) had CRP >5 
mg/L or ESR ≥28 mm/h; (4) had an inadequate clin-
ical response to methotrexate (MTX) at a dose of 10–25 
mg/week following dose escalation according to local 
standards (those who had failed a DMARD other than 
MTX, and any other DMARD used in combination with 
MTX prior to baseline, were allowed after an appropriate 
wash-out period of 4 weeks); (5) were on MTX therapy 
for ≥3 months and on a stable dose for ≥28 days prior to 
baseline; (6) were on stable dose of folic acid (≥5 mg per 
week) for ≥28 days before baseline.
The key exclusion criteria included (1) any previous 
exposure to ETN; (2) treatment with any other biologic 
therapy for RA, including TNF inhibitors, anti-CD20, 
immune-modulator drug(s), other investigational 
drug(s) and/or device(s) within 3 months or five half-
lives at the time of enrolment, whichever was longer; (3) 
previous use of >2 biologics (allowed only if the therapy 
was efficient and not failing and was withdrawn because 
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Figure 1 Patient disposition (full analysis set). Patients completing week 24 visit are considered completing TP1. ETN, 
reference etanercept; TP1, treatment period 1.
of other reasons that were not due to efficacy failure or 
safety issues); (4) investigator-determined primary-line 
and secondary-line biologic therapy failures; (5) patients 
taking high-potency opioid analgesics, and/or any intra-
muscular corticosteroid injection, and/or any therapy by 
intra-articular injection required for treatment of acute 
RA flare within 4 weeks before baseline; (6) functional 
status class IV according to the ACR 1991 revised criteria19; 
(7) systemic manifestations of RA, with the exception of 
Sjögren’s syndrome; (8) any other active inflammatory or 
autoimmune diseases other than RA; and (9) history of 
tuberculosis and latent tuberculosis detected by imaging 
and/or by the QuantiFERON®-TB Gold test at screening 
(see online supplementary appendix 1 for detailed exclu-
sion criteria).
Concomitant and prohibited medications
All patients continued to receive concomitant MTX at 
a stable dose (10–25 mg/week) and folic acid (≥5 mg/
week) until the end of the study. Patients on a stable dose 
of oral corticosteroids (prednisone ≤7.5 mg or equiva-
lent) or non-steroidal anti-inflammatory drugs/cyclooxy-
genase-2 inhibitors and paracetamol/low-strength opioids 
for at least 4 weeks before randomisation were allowed to 
continue the treatment during the study, if necessary. Use 
of rescue medication was not allowed.
During the study, the following medications were prohib-
ited: (1) any biologic or conventional synthetic DMARDs 
and/or immunosuppressants other than MTX; (2) any 
intra-articular injection (ie, corticosteroid, hyaluronan); 
(3) any intramuscular corticosteroid injection; (4) any 
intra-articular or any systemic corticosteroid treatment; (5) 
administration of live vaccines.
statistical analysis
Assuming no difference between GP2015 and ETN, a 
sample size of 183 patients per treatment group was calcu-
lated (to obtain 155 evaluable patients per treatment 
group, with an assumed drop-out and major protocol devi-
ation rate of 15%), which was estimated to provide 90% 
power for the primary endpoint analysis.
DAS28-CRP was chosen as the primary endpoint of this 
study as it is a continuous measure and is more sensitive 
compared with categorical measures, such as ACR20. In 
addition, DAS28-CRP is a clinically relevant and widely 
accepted endpoint across RA studies and has been exten-
sively validated for its use in clinical trials in combination 
with EULAR response criteria.20
Therapeutic equivalence, in terms of change from base-
line in DAS28-CRP, could be established if the 95% CI for 
the difference in mean changes was contained within the 
interval (−0.6 to 0.6). A mixed-model repeated measures 
analysis was performed for the primary variable to calculate 
the 95% CI at week 24 including treatment as a fixed effect. 
The model adjusted for the following stratification factors: 
weight (<90 kg), prior DMARD strata time (visits), the 
interaction between time (visits) and treatment, all as cate-
gorical variables, and baseline DAS28-CRP as a continuous 
variable. No imputation was performed for the missing 
components of the DAS28-CRP score.
All efficacy analyses were performed on the TP1 per-pro-
tocol set (PPS) that consisted of all patients who completed 
the study until week 24 without major protocol deviations. 
The analyses were repeated on the TP1 full analysis set (TP1 
FAS) that included all randomised patients to whom study 
treatment had been assigned. Safety and immunogenicity 
results were summarised descriptively for the TP1 safety set 
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Table 1* Baseline characteristics and disease history (TP1 full analysis set)
Characteristics
GP2015
(n=186)
ETN
(n=190)
Age (years) 55.2 (11.22) 53.1 (12.70)
Male, n (%) 28 (15.1) 40 (21.1)
Race, n (%) 
  Caucasian 180 (96.8) 185 (97.4)
  African American 5 (2.7) 1 (0.5)
  Asian 0 3 (1.6)
  American Indian or Alaska Native 1 (0.5) 1 (0.5)
DAS28-CRP 5.43 (0.92) 5.55 (0.78)
Tender 28-joint count 14.2 (6.18) 14.8 (5.78)
Swollen 28-joint count 10.5 (5.28) 11.1 (5.39)
C reactive protein (mg/L) 11.7 (21.09) 11.0 (15.83)
HAQ-DI score 1.45 (0.55) 1.44 (0.58)
FACIT fatigue score 26.95 (9.60) 25.28 (10.09)
Duration of rheumatoid arthritis (years) 8.79 (8.25) 8.18 (6.92)
Rheumatoid factor, positive, n (%) 137 (73.70) 140 (73.70)
Anti-CCP, positive, n (%) 144 (77.40) 140 (73.70)
Prior therapy*, n (%)
  MTX only 56 (30.1) 58 (30.5)
  MTX+any DMARDs 73 (39.2) 72 (37.9)
  MTX+any anti-TNF 31 (16.7) 33 (17.4)
  MTX+any other biologic 26 (14.0) 27 (14.2)
Previous DMARDs used, n (%)
  1 56 (30.1) 58 (30.5)
  2 75 (40.3) 69 (36.3)
  3 36 (19.4) 39 (20.5)
  4 or more 19 (10.2) 24 (12.6)
MTX dose (mg/week) 16.0 (4.9) 17.1 (4.6)
Prior duration of MTX (months) 55.6 (49.7) 59.5 (51.7)
Prior therapy strata is arranged according to the hierarchy; values are mean (SD) unless otherwise stated; rheumatoid factor ≤10 IU/mL 
and anti-CCP <17 U/mL are considered negative.
CCP, cyclic citrullinated peptide; DAS28-CRP, disease activity score 28-joint count C reactive protein; DMARD, disease-modifying 
antirheumatic drug; ETN, reference etanercept; FACIT, Functional Assessment of Chronic Illness Therapy; HAQ-DI, Health Assessment 
Questionnaire Disability Index; MTX, methotrexate; TNF, tumour necrosis factor; TP1, treatment period 1.
(SAF) that included all patients who received at least one 
dose of study treatment during the treatment period.
ResulTs
Patient disposition
Of the 376 patients randomised, 353 completed TP1 
(figure 1) while 23 patients were discontinued in both 
treatment groups; the main reason for discontinuation was 
withdrawal of consent. The TP1 FAS and SAF included all 
376 randomised patients, and the TP1 PPS included 323 
patients. The main reasons for excluding patients from the 
PPS included (1) deviation from key (diagnostic) and effi-
cacy-related eligibility criteria, (2) prohibited concomitant 
medication or procedure, and (3) failure to perform key 
and safety procedures.
Baseline characteristics
Patients had a mean age of 54.1 years (SD 12.02), and 
the majority were females (n=308; 81.9%) and Cauca-
sian (n=365; 97.1%). The majority (68.6%) of patients 
had received prior treatment with one or two DMARDs. 
The baseline demographics and disease characteristics 
of patients were comparable across treatment groups 
(table 1). Prior anti-TNF and other biologics use was well 
balanced between treatment arms.
Primary outcome
In the TP1 PPS, the least squares mean difference for 
change in DAS28-CRP from baseline to week 24 between 
GP2015 and ETN (GP2015–ETN) was −0.07 (95% CI 
−0.26 to 0.12; figure 2). The 95% CI was well contained 
within the prespecified equivalence margin of −0.6 to 0.6 
 o
n
 10 Decem
ber 2018 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000757 on 14 Novem
ber 2018. Downloaded from
 
5Matucci-cerinic M, et al. RMD Open 2018;4:e000757. doi:10.1136/rmdopen-2018-000757
Rheumatoid arthritis
Figure 2 DAS28-CRP change from baseline over 24 weeks (TP1 per-protocol set) at baseline, the mean DAS28-CRP was 
5.42 and 5.53 for GP2015 and ETN groups, respectively. The per-protocol set consists of all patients completing the study until 
week 24 without major protocol deviations. Error bars represent the SE. *Primary endpoint; †95% CI was contained within the 
prespecified equivalence margin of −0.6 to 0.6; a mixed-model repeated measures analysis was performed for DAS28-CRP 
change from baseline using the TP1 per-protocol set. Equivalence was further confirmed with the analysis on the FAS (least 
squares mean difference: −0.06 (95% CI −0.25 to 0.12)). Per-protocol set: GP2015 (n=168), ETN (n=155). DAS28-CRP, disease 
activity score 28-joint count C reactive protein; ETN, reference etanercept; LS, least squares; TP1, treatment period 1.
demonstrating therapeutic equivalence between GP2015 
and ETN. Equivalence was further confirmed with the 
analysis on the FAS (least squares mean difference: −0.06 
(95% CI −0.25 to 0.12)).
Key secondary outcomes
efficacy
The mean (SD) DAS28-CRP change from baseline to 
week 24 was similar between the GP2015 (−2.78 [1.1]) 
and ETN groups (−2.78 [1.0]; figure 3A).
At 24 weeks, EULAR moderate and good response 
rates improved and were again comparable between the 
GP2015 and ETN (figure 3B) groups.
The ACR20, ACR50 and ACR70 response rates were 
comparable between the GP2015 and ETN groups over 
24 weeks (figure 4). At week 24, ACR20, ACR50 and 
ACR70 response rates were 88%, 64.1% and 33.5%, 
respectively, in the GP2015 group and 92.9%, 71.0% and 
42.6%, in the ETN group, respectively.
Improvements from baseline in HAQ-DI and FACIT 
fatigue scores were comparable between the GP2015 and 
ETN groups over 24 weeks. At week 24, the mean change 
from baseline in HAQ-DI score was −0.57 in the GP2015 
group and −0.67 in the ETN group (online supple-
mentary figure S2). The mean change from baseline in 
FACIT fatigue score at week 24 was 9.45 in the GP2015 
group and 11.82 in the ETN group, respectively (online 
supplementary figure S3). The DAS28-CRP change from 
baseline at week 24 for the different subgroups by prior 
treatment is provided in online supplementary table S1.
Safety
The median duration of exposure was similar between 
the GP2015 and ETN groups (162 days). The number 
of patients with at least one treatment-emergent 
adverse event (TEAE) up to 24 weeks was comparable 
between the GP2015 (n=81 [43.5%]) and ETN (n=94 
[49.5%]) group (table 2). At least one TEAE and the 
most commonly (≥2% incidence) reported TEAEs up 
to 24 weeks occurred in a similar proportion of patients 
in the GP2015 and ETN groups (table 2). Injection-site 
reactions were reported as TEAEs in fewer patients 
in the GP2015 group (13 [7.0%]) compared with the 
ETN group (35 [18.4%]); all were mild or moderate in 
intensity and none were considered as a serious adverse 
event.
In both groups during TP1, injection-site reactions, 
mostly mild, were the treatment-related TEAE with 
higher incidence in the ETN (18.4%) group compared 
with the GP2015 group (6.5%; online supplementary 
table S2). Serious AEs were reported in one (0.5%) 
patient in the GP2015 group (spinal fracture caused by 
injury) and five (2.6%) patients in the ETN group (atrial 
fibrillation, cholelithiasis, hepatic enzyme increase, 
worsening RA, lung neoplasm [n=1 each]). In the ETN 
group, one patient died during the study due to malig-
nant lung neoplasm. As assessed by the investigator, 
the serious adverse event (SAE) lung cancer was severe 
with no suspected causal relationship to study drug. The 
patient was a smoker (40 cigarettes per day) with a family 
history of cancer. Two (1.1%) patients in the GP2015 
group and seven (3.7%) in the ETN group discontinued 
due to TEAEs during TP1, with one patient each with 
pruritic rash and decreased platelet count in the GP2015 
group. In the ETN group, discontinuations were due to 
urticaria, RA flare, thrombocytopenia/injection-site reac-
tion, lung neoplasm in one case each and injection site 
reactions in another three cases. TEAEs of special interest 
were infrequently reported in either the GP2015 or ETN 
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Figure 3 (A) Mean change from baseline in DAS28-CRP scores over 24 weeks (TP1 per-protocol set). The per-protocol set 
consists of all patients completing the study until week 24 without major protocol deviations. Error bars represent the SE. Per-
protocol set: GP2015 (n=168), ETN (n=155). (B) EULAR response rates over 24 weeks (TP1 per-protocol set). The per-protocol 
set consists of all patients completing the study until week 24 without major protocol deviations. EULAR good response is 
defined as DAS28 ≤3.2 at week 24 and improvement from baseline >1.2; EULAR moderate response is defined as DAS28 >3.2 
and ≤5.1 at week 24 and improvement from baseline >0.6 or DAS28 >5.1 at week 24 and improvement from baseline >1.2. 
Per-protocol set: GP2015 (n=168), ETN (n=155). DAS28-CRP, disease activity score 28-joint count C reactive protein; ETN, 
reference etanercept; EULAR, European League Against Rheumatism; TP1, treatment period 1.
Figure 4 ACR20/50/70 response rates at week 24 (TP1 per-protocol set). The per-protocol set consists of all patients 
completing the study until week 24 without major protocol deviations. Per-protocol set: GP2015 (n=168), ETN (n=155). 
ACR20/50/70, American College of Rheumatology 20%/50%/70% response criteria; ETN, reference etanercept; TP1, treatment 
period 1.
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Table 2 TEAEs and SAEs during the 24-week treatment period (TP1 safety set)
Preferred term
GP2015
(n=186)
n (%)
ETN
(n=190)
n (%)
≥1 TEAE 81 (43.5) 94 (49.5)
≥1 SAE 1 (0.5) 5 (2.6)
≥1 Treatment-related TEAE 39 (21.0) 46 (24.2)
≥1 Treatment-related SAE 0 0
Discontinuations due to TEAE 2 (1.1) 7 (3.7)
≥1 AE of special interest 12 (6.5) 9 (4.7)
Deaths 0 1 (0.5)
TEAEs with a ≥2% incidence in any of the treatment groups
  Injection-site reaction 13 (7.0) 35 (18.4)
  Nasopharyngitis 9 (4.8) 4 (2.1)
  Alanine aminotransferase increased 8 (4.3) 4 (2.1)
  Urinary tract infection 8 (4.3) 8 (4.2)
  Upper respiratory tract infection 6 (3.2) 7 (3.7)
  Back pain 5 (2.7) 1 (0.5)
  Diarrhoea 3 (1.6) 4 (2.1)
  Bronchitis 2 (1.1) 4 (2.1)
  Cystitis 2 (1.1) 4 (2.1)
A patient with multiple occurrences of event within the same system organ class or preferred term under one treatment is counted only once. 
TEAEs are events started after the first dose of study treatment and before study discontinuation or 30 days after the last dose, whichever 
occurs later. Adverse event terms are coded using MedDRA V.19.1.
ETN, reference etanercept; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event; TEAE, treatment-emergent 
adverse event; TP1, treatment period 1.
group (6.5% vs 4.7%, respectively; online supplementary 
table S3).
immunogenicity
In both groups, ADAs were detected between weeks 2 
and 12. While ADA incidence in general was low, ADA 
positivity peaked in a singular point at week 4 (GP2015: 
1.6%; ETN: 22.7%). The titre of all measured ADAs was 
low and near the detection limit of a highly sensitive 
method. None of the GP2015-treated patients developed 
neutralising antibodies (NAbs) whereas 1.6% and 0.6% 
of patients in ETN group were NAb positive at weeks 4 
and 12, respectively. Of note, all ADA/NAb responses 
were transient and none of the patients had detectable 
ADA or NAb levels at week 24 (online supplementary 
figure S4).
dIsCussIOn
The EQUIRA study met the primary endpoint showing 
that GP2015 has equivalent efficacy to ETN in patients 
with RA, who had an inadequate response to synthetic 
or biologic DMARDs. This finding was further supported 
by the evidence that secondary efficacy endpoints were 
clearly comparable between GP2015 and ETN. The data 
were also strengthened by the evidence that other items 
such as patient-reported outcomes were also comparable 
between the two treatments.
The study design attributes, as well as the key features 
of the EQUIRA study, such as patient population, inclu-
sion criteria, prior therapy including stable dose of MTX 
and efficacy evaluations, were aligned with the key phase 
III trials for RA conducted with ETN. Although the dose 
of ETN used in the pivotal trials was 25 mg twice weekly, 
similar clinical outcomes, safety and pharmacokinetic 
profiles have previously been demonstrated for the 50 mg 
dose administered once weekly in patients with RA.21 The 
population was predominantly Caucasian in this study.
In the EQUIRA study, the use of DAS28-CRP as the 
primary endpoint allowed for a direct comparison with 
relevant literature data and a comprehensive interpre-
tation of the study results. The therapeutic equivalence 
for the DAS28-CRP change from baseline to week 24 was 
achieved. In addition, considering that previous ETN 
studies have assessed both DAS28 and ACR response,22–24 
ACR20 and other ACR responses were assessed as 
secondary endpoints in order to better compare the 
results of the current study with historical data and to 
ensure complete evaluation of clinical efficacy.
The ACR20 response rates in the GP2015 and ETN 
groups at week 24 (88% vs 92.9%, respectively) were 
comparable although slightly higher than those reported 
in previous ETN studies.25 26 The biosimilar study 
design uses active treatment arms and lacks a placebo 
comparator, and it has been reported previously that 
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higher ACR20 response rates are observed in biosimilar 
studies compared with placebo-controlled studies.27–29 
The higher ACR20 response rates at week 24 in both 
treatment groups in this study may also be due to high 
numbers of (1) biologic-naïve patients and (2) patients 
with low or no prior exposure to DMARDs in combina-
tion with MTX.
It is important to remark that over 24 weeks, the inci-
dence of TEAEs was comparable between the two treat-
ment groups. No new safety findings or concerns were 
reported. Overall, GP2015 was well tolerated with a 
similar safety profile to the well-established safety profile 
of ETN.3 The incidence of injection site reactions was 
lower in the GP2015 (7.0%) than in the ETN group 
(18.4%), similar to those observed in recent biosimilar 
ETN studies.28 30 31 Similar differences between GP2015 
and ETN were also observed in the EGALITY study in 
patients with plaque-type psoriasis.8 This could be due to 
differences in the formulations between the two drugs, as 
reported for other ETN biosimilars.28 30
In this study, immunogenicity assessment was 
performed using a validated state-of-the-art technique 
comprising a high sensitivity and drug tolerance which 
enables the detection of low titre and transient ADAs 
even during the drug treatment phase. As recently recom-
mended,32 a false-positive rate for confirmatory assay 
of 1% was applied instead of the commonly used 0.1% 
rate.33 Applying both a sensitive and drug-tolerant assay 
as well as a contemporary biostatistical approach may 
lead to a higher reported ADA incidence compared with 
historical data.17 While ADA incidence was consistently 
low in the GP2015 treatment group, a singular peak of 
ADA positivity was observed at week 4 for ETN-treated 
patients also including NAbs. Beside the evaluation of 
ADA/NAb incidence, a correlation of immunogenicity 
outcome to efficacy or patients’ safety was not observed, 
indicating that detected ADAs were not clinically rele-
vant. This may be explained by the transient nature of 
the detected ADAs (including NAbs) as well as the low 
titre results.
COnClusIOns
The EQUIRA study demonstrated an equivalent efficacy 
of GP2015 and ETN in patients with RA with moderate 
to severe disease with inadequate responses to DMARDs, 
including MTX and biologics. The safety profiles of 
GP2015 and ETN were comparable and no new safety 
findings or concerns were reported. These results 
obtained in patients with RA are a further complement to 
prior evidence indicating equivalent efficacy of GP2015 
and ETN in plaque-type psoriasis.
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